CGEM
Cullinan Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website cullinanoncology.com
- Employees(FY) 62
- ISIN US2300311063
Performance
+8.22%
1W
+72.44%
1M
+58.91%
3M
+199.49%
6M
+188.03%
YTD
+208.62%
1Y
Profile
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: CGEM
Overview
CGEM operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has shown significant growth in its financial metrics over the past three years, with a notable increase in total assets, revenue, and net income. This report will delve into the valuation, fin...
Technical Analysis of CGEM 2024-05-03
Overview:
In analyzing the technical indicators for CGEM over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...
Recent News & Updates
- 2024-05-01 07:05
- 2024-04-29 07:00
- 2024-04-28 19:00
- 2024-04-24 16:29
- 2024-04-24 10:09
- 2024-04-23 22:09
- 2024-04-16 15:32
- 2024-04-16 07:00
- 2024-04-16 06:59
- 2024-04-16 04:48
Cullinan changes name, pivots to autoimmune disease(BioPharma Dive)
- 2024-04-15 19:00
- 2024-04-15 18:59
- 2024-03-16 05:31
- 2024-03-15 07:34
- 2024-03-14 07:00
- 2024-03-14 00:53
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023(Investorplace)
- 2024-03-13 19:00
- 2024-03-01 07:00
- 2024-02-27 08:00
- 2024-02-26 19:00
- 2024-02-21 09:21
13 Best Booming Stocks to Buy Right Now(Insider Monkey)
- 2024-02-02 23:01
- 2024-01-30 23:01
- 2024-01-24 19:02
- 2023-12-18 16:53
- 2023-12-18 03:53
- 2023-12-14 16:30
- 2023-12-14 03:30
- 2023-11-08 07:00
- 2023-11-07 18:00
Page 1 of 5
previousnext